Diagonal Therapeutics’ New Slant Attracts $128M to Reactivate Antibody Drug R&D
Alex Lugovskoy, CEO of Diagonal Therapeutics, aims to develop antibodies that activate targets, rather than just inhibit cellular functions. Using computational and experimental techniques, the startup focuses on binding combinations to yield desired effects. Diagonal’s platform, developed over two years, includes a lead program for a rare bleeding disorder without FDA-approved therapies. Their technology, which…